Genetic alterations that activate the mitogen-activated protein kinase (MAP kinase) pathway
occur commonly in cancer. For example, the majority of melanomas harbor mutations in the …

A detailed understanding of the mechanisms by which tumors acquire resistance to targeted
anticancer agents should speed the development of treatment strategies with lasting clinical …

Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients
develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a …

Abstract Although targeting the Ras/Raf/MEK pathway remains a promising anticancer
strategy, mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK) …

Abstract The RAS/RAF/MEK pathway is activated in more than 30% of human cancers, most
commonly via mutation in the K-ras oncogene and also via mutations in BRAF. Several …

KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of
the MAPK pathway. As these tumours represent an area of high unmet medical need …

BRAF inhibitors (BRAFi) induce antitumor responses in nearly 60% of patients with
advanced V600E/K BRAF melanomas. Somatic activating MEK1 mutations are thought to be …

Mutations at multiple sites in MEK1 occur in cancer, suggesting that their mechanisms of
activation might be different. We analyzed 17 tumor-associated MEK1 mutants and found …

Background: MEK1 mutations in melanoma can confer resistance to BRAF inhibitors,
although preexisting MEK1P124 mutations do not preclude clinical responses. We sought to …

The use of targeted therapeutics directed against BRAFV600-mutant metastatic melanoma
improves progression-free survival in many patients; however, acquired drug resistance …